Cargando…

Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways

OBJECTIVES: This study sought to investigate the genome-wide transcriptional effects of a combination of disease modifying anti-rheumatic drugs (tDMARD; methotrexate, sulfasalazine and hydroxychloroquine) in synovial tissues obtained from early rheumatoid arthritis (RA) patients. While combination D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walsh, Alice M., Wechalekar, Mihir D., Guo, Yanxia, Yin, Xuefeng, Weedon, Helen, Proudman, Susanna M., Smith, Malcolm D., Nagpal, Sunil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580991/ https://www.ncbi.nlm.nih.gov/pubmed/28863153 http://dx.doi.org/10.1371/journal.pone.0183928

Ejemplares similares

Differential expansion of T peripheral helper cells in early rheumatoid arthritis and osteoarthritis synovium
por: Murray-Brown, William, et al.
Publicado: (2022)

Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy
por: Murray-Brown, William, et al.
Publicado: (2020)

Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs
por: Daraghmeh, Dala N, et al.
Publicado: (2022)

Transcriptomic profiling of programmed cell death 1 (PD-1) expressing T cells in early rheumatoid arthritis identifies a decreased CD4 + PD-1 + signature post-treatment
por: Lowe, Katie, et al.
Publicado: (2023)

Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus
por: Cole, Suzanne, et al.
Publicado: (2018)

Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression
por: Guo, Yanxia, et al.
Publicado: (2018)

Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue
por: Triaille, Clement, et al.
Publicado: (2021)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
por: Bhushan, Vandana, et al.
Publicado: (2021)

Editorial: Synovial pathobiology and pathogenesis of inflammatory arthritis
por: Small, Annabelle, et al.
Publicado: (2022)

Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis
por: Gomez, Esteban A., et al.
Publicado: (2020)

Editorial: Synovial tissue biopsy research
por: Veale, Douglas J., et al.
Publicado: (2022)

Artificial intelligence and the future of radiographic scoring in rheumatoid arthritis: a viewpoint
por: Bird, Alix, et al.
Publicado: (2022)

Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis
por: Brown, Zoe, et al.
Publicado: (2020)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Plasmablastic plasma cell myeloma mimicking plasmablastic lymphoma
por: Choi, Qute, et al.
Publicado: (2010)

Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years
por: Wabe, Nasir, et al.
Publicado: (2015)

Are DMARDs enough to prevent surgery in rheumatoid hands?
por: Sim, Yeap Swan
Publicado: (2015)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
por: Humby, Frances, et al.
Publicado: (2019)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8)
por: Kraan, Maarten C, et al.
Publicado: (2001)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
por: Wei, Kai, et al.
Publicado: (2022)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Attenuation of the BTLA/HVEM Regulatory Network in the Circulation in Primary Sjögren’s Syndrome
por: Small, Annabelle, et al.
Publicado: (2022)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Increased Galectin-9 Levels Correlate with Disease Activity in Patients with DMARD-Naïve Rheumatoid Arthritis and Modulate the Secretion of MCP-1 and IL-6 from Synovial Fibroblasts
por: Nielsen, Morten A., et al.
Publicado: (2023)

Memory B cell subsets and plasmablasts are lower in early than in long-standing Rheumatoid Arthritis
por: Fedele, Anna Laura, et al.
Publicado: (2014)

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2014)

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
por: Voshaar, M. J. H., et al.
Publicado: (2022)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

Autoreactive B cells in rheumatoid arthritis include mainly activated CXCR3(+) memory B cells and plasmablasts
por: Reijm, Sanne, et al.
Publicado: (2023)

Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients
por: Burkard, Theresa, et al.
Publicado: (2021)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts
por: Müller-Ladner, Ulf, et al.
Publicado: (2007)

Plasmablastic lymphoma in Malawi
por: Zuze, Takondwa, et al.
Publicado: (2018)

Correction to: Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Luurssen-Masurel, Nathalie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jumhmck1f29rpq9gqjub8317j4